La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Phibro Animal Health a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Phibro Animal Health..

Phibro Animal Health (NASDAQ:PAHC) Azioni, Catena delle Opzioni

Phibro Animal Health

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health Corp

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Phibro Animal Health to report an earnings per share (EPS) of $0.25.
Phibro Animal Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 3.17% increase in the share price on the subsequent day.
Here's a look at Phibro Animal Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.29</td>
<td>0.28</td>
<td>0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.41</td>
<td>0.31</td>
<td>0.33</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730836895_0.png" alt="eps graph" />
<h3>Market Performance of Phibro Animal Health's Stock</h3>
Shares of Phibro Animal Health were trading at $22.37 as of November 04. Over the last 52-week period, shares are up 90.95%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Phibro Animal Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Phibro Animal Health.
Analysts have provided Phibro Animal Health with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $18.5, suggesting a potential 17.3% downside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Liquidia, Evolus and EyePoint Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Liquidia, with an average 1-year price target of $26.08, implying a potential 16.58% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.0, implying a potential 7.29% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $24.0, suggesting a potential 7.29% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Liquidia, Evolus and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phibro Animal Health</td>
<td>Neutral</td>
<td>7.10%</td>
<td>$87.15M</td>
<td>0.29%</td>
</tr>
<tr>
<td>Liquidia</td>
<td>Buy</td>
<td>-23.55%</td>
<td>$2.17M</td>
<td>-37.51%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>4.09%</td>
<td>$8.08M</td>
<td>-12.89%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Phibro Animal Health ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>Unveiling the Story Behind Phibro Animal Health</h3>
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
<h3>Understanding the Numbers: Phibro Animal Health's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Phibro Animal Health showcased positive performance, achieving a revenue growth rate of 7.1% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Phibro Animal Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.28%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phibro Animal Health's ROA excels beyond industry benchmarks, reaching 0.08%. This signifies efficient management of assets and strong financial health.
Debt Management: Phibro Animal Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.05, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/PAHC/earnings">To track all earnings releases for Phibro Animal Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

PAHC

What's Next: Phibro Animal Health's Earnings Preview

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Friday.
Shares of Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell sharply in today's pre-market trading after the company lowered its annual production guidance due to supply shortage of shared component on the <a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling">R1 and RCV platforms</a>.
The company produced 13,157 vehicles at its manufacturing facility in Normal, Illinois, and delivered 10,018 cars during the same period. Rivian is experiencing a supply shortage that began in the third quarter of this year and has intensified in recent weeks.
Rivian Automotive shares dipped 6.8% to $10.05 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 11.3% to $6.20 in pre-market trading.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 7% to $20.17 in pre-market trading after falling around 7% on Thursday.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) shares fell 5.7% to $2.3290 in pre-market trading. Hyliion recently announced its KARNO linear generator now qualifies under California&#8217;s renewables portfolio standard.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) shares fell 5.4% to $20.00 in pre-market trading,</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares fell 5.2% to $4.95 in pre-market trading after jumping over 33% on Thursday.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares declined 4.4% to $6.04 in pre-market trading. EVgo shares jumped more than 60% on Thursday after the company announced it received a $1.05 billion conditional commitment for a Department of Energy (DOE) loan guarantee to accelerate the buildout of public fast charging across the US.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

EVGO

HYLN

RIVN

SAGE

Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Bruker Corporation&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company&#39;s operational results.
In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have gained 10.4% compared with the industry&#39;s 27.5% growth and the S&amp;P 500 composite&#39;s 34.9% gain.
This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry&#39;s 13.8% growth rate. BRKR&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.
Let&#39;s delve deeper.
<h2>Bruker&#39;s Key Upsides</h2>
Bright Prospects Within Nano Business Segment:&nbsp;The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.&nbsp;
During the first half of 2024, the company&#39;s advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano&#39;s robust revenue growth. Nano&#39;s strong growth is driven by the rising demand in academic and government markets. The Nanostring acquisition is expected to be both strategically and financially beneficial, promising a high return on investment for Bruker.
The Potential of Preclinical Imaging (PCI) Market: Per Grand View Research, the global PCI market was valued at $4.30 billion in 2023 and is likely to witness a CAGR of 4.6% up to 2030. Therefore, this translates into a golden opportunity for Bruker to expand its foothold in the PCI market and earn higher profits from this division.
Bruker offers advanced PCI solutions for a broad spectrum of application fields. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems. Earlier this year, Bruker filled a critical gap in its PCI portfolio with the acquisition of Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.
<h2>Bruker&#39;s Key Downsides</h2>
Unfavorable Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.&nbsp; As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations are likely to cause the price of Bruker&#39;s products to be less competitive than its principal competitors&#39; offerings.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/80173.jpg?v=35874249" />
Image Source: Zacks Investment Research
Macroeconomic Factors:&nbsp;Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions are impacting its operational results. In addition, supply-chain risks also persist. All these issues are leading to higher costs and expenditures for the company, impacting its profitability.
In the second quarter, Bruker&#39;s cost of revenues increased 21.6% from the same period in 2023. SG&amp;A expenses surged 24.4%.
<h2>BRKR&#39;s Estimate Trend</h2>
The Zacks Consensus Estimate for Bruker&#39;s 2024 earnings per share remained unchanged at $2.61 for the past 30 days.
The consensus estimate for the company&#39;s 2024 revenues is pegged at $3.41 billion, indicating a 14.9% rise from the year-ago &nbsp;number.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are&nbsp;TransMedix Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 173.5% in the past year compared with the industry&#39;s 22.4% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present.
AxoGen, carrying a Zacks Rank #2 (Buy) at present, has an earning yield of 94.1% compared with the industry&#39;s 12.3%. Shares of the company have risen 194.6% compared with the industry&#39;s 22.3% growth over the past year.&nbsp;AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry&#39;s 12.6%. In the past year, shares of PAHC have risen 72.7% compared with the industry&#39;s 25.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.
<a href="https://www.zacks.com/stock/news/2345297/here-s-why-you-should-retain-brkr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2345297">To read this article on Zacks.com click here.</a>

Earnings Beats

Macro Economic Events

Mid Cap

Offerings

Small Cap

Economics

Analyst Ratings

AXGN

BRKR

TMDX

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

JP Morgan analyst Ekaterina Knyazkova initiates coverage on Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Neutral rating and announces Price Target of $22.

Price Target

Initiation

JP Morgan Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $22

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Domo</h3>
<ul>
<li>The Trade: Domo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) CFO David R Jolley <a href="https://www.benzinga.com/quote/DOMO/analyst-ratings">acquired a total of 10,000 shares at</a> an average price of $6.99. To acquire these shares, it cost around $69,875.</li>
<li>What's Happening: On Aug. 29, Domo posted better-than-expected quarterly results.</li>
<li>What Domo Does: Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones.</li>
</ul>
<h3 class="wp-block-heading">Phibro Animal Health</h3>
<ul>
<li>The Trade: Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) Director E Thomas Corcoran acquired a total of 5,000 shares at an average price of $20.02. To acquire these shares, it cost around $100,100.</li>
<li>What's Happening: On Aug. 28, Phibro Animal Health posted upbeat quarterly earnings.</li>
<li>What Phibro Animal Health Does: Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company.</li>
</ul>
<h3 class="wp-block-heading">BJ&#8217;s Restaurants</h3>
<ul>
<li>The Trade: BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) Interim CEO C Bradford Richmond <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 2,500 shares</a> at an average price of $29.40. To acquire these shares, it cost around $73,500.</li>
<li>What's Happening: On Sept. 3, BJ&#8217;s Restaurants announced appointment of President &amp; Chief Concept Officer.</li>
<li>What BJ&#8217;s Restaurants Does: BJ&#8217;s Restaurants Inc is involved in the business of owning and operating restaurants.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40748893/over-40m-bet-on-pbf-energy-check-out-these-4-stocks-executives-are-buying">Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying</a></li>
</ul>

Long Ideas

Insider Trades

BJRI

DOMO

Executives Buying BJ's Restaurants And 2 Other Stocks

Momentum investing revolves around the idea of following a stock&#39;s recent trend in either direction. In the &#39;long&#39; context, investors will be essentially be &quot;buying high, but hoping to sell even higher.&quot; With this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Phibro Animal Health currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
<h2>Set to Beat the Market?</h2>
Let&#39;s discuss some of the components of the Momentum Style Score for PAHC that show why this maker of animal health products and nutritional supplements shows promise as a solid momentum pick.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For PAHC, shares are up 0.29% over the past week while the Zacks Medical - Products industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 11.23% compares favorably with the industry&#39;s 1.3% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Phibro Animal Health have risen 9.22%, and are up 55.61% in the last year. On the other hand, the S&amp;P 500 has only moved 3.12% and 23.92%, respectively.
Investors should also pay attention to PAHC&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. PAHC is currently averaging 181,236 shares for the last 20 days.
<h2>Earnings Outlook</h2>
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with PAHC.
Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost PAHC&#39;s consensus estimate, increasing from $1.42 to $1.46 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
<h2>Bottom Line</h2>
Given these factors, it shouldn&#39;t be surprising that PAHC is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep Phibro Animal Health on your short list.
<a href="https://www.zacks.com/stock/news/2333000/are-you-looking-for-a-top-momentum-pick-why-phibro-animal-health-pahc-is-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2333000">To read this article on Zacks.com click here.</a>

Are You Looking for a Top Momentum Pick? Why Phibro Animal Health is a Great Choice

B of A Securities analyst Derik De Bruin maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underperform and raises the price target from $13 to $15.

B of A Securities Maintains Underperform on Phibro Animal Health, Raises Price Target to $15

Phibro Animal Health&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) delivered adjusted earnings per share of 41 cents in the fourth quarter of fiscal 2024, up 7.9% from the year-ago quarter&#39;s level. The bottom line beat the Zacks Consensus Estimate by 20.6%.
Without adjustments, the GAAP EPS in the quarter was 2 cents, down 92.9% from the year-ago quarter&#39;s figure.
PAHC reported full-year adjusted EPS of $1.19, reflecting a 1.7% decline from fiscal 2023. The figure beat the Zacks Consensus Estimate by 6.25%.
<h2>PAHC&#39;s Net Sales</h2>
In the quarter under review, net sales totaled $273.2 million, up 7.1% from the year-ago quarter&#39;s level. The figure also topped the Zacks Consensus Estimate by 4.1%.
For fiscal 2024, the company reported net sales of $1.02 billion, up 4.1% from the prior-year level. The figure beat the Zacks Consensus Estimate by a marginal 1%.
<h2>Phibro&#39;s Segmental Sales</h2>
The company conducts its operations via three segments &mdash; Animal Health, Mineral Nutrition and Performance Products.
In the fourth quarter of fiscal 2024,&nbsp;Animal Health&#39;s net sales increased 8% to $191.5 million. Within the segment, net sales of medicated feed additives (MFAs) and others reflected 12% year-over-year growth. The uptick was driven by the increased demand for MFAs in both domestic and international regions and higher demand for processing aids used in the ethanol fermentation industry. The top line surpassed our model&#39;s projection of $181.8 million by 5.3%.
Nutritional specialty product sales decreased 4%, primarily due to lower demand for dairy products. However, net vaccine sales showed a year-over-year rise of 14%, mostly due to poultry product introductions in Latin America, along with an increase in domestic and international demand.
Net sales in the&nbsp;Mineral Nutrition&nbsp;segment rose 6% year over year to $62.1 million due to increased sales volume and higher average selling price. The top line surpassed our model&#39;s projection of $61.9 million by a marginal 0.3%.
Net sales in the&nbsp;Performance Products&nbsp;segment fell 1% to $19.6 million as a result of the decreased demand for personal care product ingredients and industrial chemicals. The top line surpassed our model&#39;s projection of $18 million by 8.9%.
<h2>Phibro Animal Health Corporation Price, Consensus and EPS Surprise</h2>
<div class="chart_embed"><img alt="Phibro Animal Health Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9c/1724935133.png" style="height:265px; width:577px" title="" /></div>
<div class="chart_embed">Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote</div>
<h2>PAHC&#39;s Margin Performance</h2>
Phibro&#39;s fiscal fourth-quarter gross profit rose 13.8% year over year to $87.2 million. The gross margin expanded 188 basis points (bps) to 31.9% despite a 4.3% rise in the cost of goods sold.
SG&amp;A expenses in the reported quarter were $68.7 million, up 29.9% from the year-ago quarter&#39;s levels. The operating profit declined 21% year over year to $18.5 million and the operating margin contracted 252 bps to 6.8% in the quarter under review.
<h2>PAHC&#39;s Financial Update</h2>
The company exited the fourth quarter of fiscal 2024 with cash and short-term investments of $114.6 million compared with $98.7 million at the end of the fiscal third quarter.
Cumulative net cash provided by operating activities at the end of fiscal 2024 was $87.6 million compared with $13.3 million in the year-ago period.
<h2>Phibro&#39;s Fiscal 2025 Guidance</h2>
The company expects net sales to be between $1.04 billion and $1.09 billion. The Zacks Consensus Estimate for the metric is pegged at $1.25 billion.
Adjusted EPS is expected to be in the range of $1.22-$1.37. The Zacks Consensus Estimate for the same is pegged at $1.43.
<h2>Our Take on Phibro&#39;s Q4 Results</h2>
Phibro delivered better-than-expected revenues and earnings in the reported quarter. The core Animal Health segment benefited from the robust performance of the vaccine, MFAs and other businesses. Additionally, the Mineral Nutrition Products segment reported year-over-year growth.
The anticipated closing of the Zoetis Medicated Feed Additive portfolio acquisition in the coming months may lead to strong earnings accretion. It can also drive investments in the faster-growing vaccines, nutritional specialties and companion animal product segments.
Meanwhile, the contraction of the operating margin in the quarter is discouraging. Declining revenues from the Performance Products segment raise concern.
<h2>PAHC&#39;s Zacks Rank &amp; Other Key Picks</h2>
Phibro currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>).
Intuitive Surgical reported a second-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has a long-term five-year earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.
TransMedics, carrying a Zacks Rank #1 at present, reported second-quarter 2024 earnings of 35 cents per share, which surpassed the Zacks Consensus Estimate by 66.7%. Revenues of $114.3 million topped the Zacks Consensus Estimate by 15.9%.
TMDX has an earnings growth rate of 51.7% for 2025 compared with the S&amp;P 500&#39;s 11.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 287.50%.
Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion outpaced the Zacks Consensus Estimate by 0.5%.
DGX has a historical five-year earnings growth rate of 7.4% compared with the industry&#39;s 4.2%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.
<a href="https://www.zacks.com/stock/news/2328933/phibro-q4-earnings-and-revenues-beat-operating-margin-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2328933">To read this article on Zacks.com click here.</a>

Large Cap

Guidance

ISRG

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

<ul>
<li>Adjusted EBITDA of&nbsp;$118 million&nbsp;to&nbsp;$126 million</li>
</ul>

Phibro Animal Health Expects FY25 Net Sales Of $1.04B - $1.09B, Est $1.13B

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.33 by 24.24 percent. This is a 7.89 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $273.200 million which beat the analyst consensus estimate of $263.245 million by 3.78 percent. This is a 7.14 percent increase over sales of $255.000 million the same period last year.

Phibro Animal Health Q4 2024 Adj. EPS $0.41 Beats $0.33 Estimate, Sales $273.200M Beat $263.245M Estimate

Cardinal Health, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH&#39;s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.
<h3>Q4 Estimates</h3>
For the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter&#39;s reported figure. The same for revenues is pinned at $58.72 billion, implying growth of 9.9% year over year.
<h3>Factors to Note</h3>
From the fiscal third quarter of 2024, Cardinal Health started reporting its results under new operating segments &mdash; Pharmaceutical and Specialty solutions, Global Medical Products and Distribution (GMPD) segment, nuclear at-Home and OptiFreight.
The third quarter of fiscal 2024 witnessed an uptick in revenues in the Pharmaceutical segment, which amounted to approximately $50.7 billion, up 9% on a year-over-year basis. The Pharmaceutical Distribution and Specialty Solutions segment&#39;s performance highlighted branded pharmaceutical sales growth from existing customers. The segment&#39;s profit increased 4% during the fiscal third quarter. This momentum is likely to have continued in the&nbsp;fiscal fourth quarter&nbsp;as well. Moreover, the rising demand for GLP-1 medications is likely to have acted as a tailwind.
Higher contributions from brand and specialty products, as well as the effectiveness of the generics program, drove the positive outcome of the pharmaceutical segment in the last reported quarter. This trend is likely to have continued in the to-be-reported quarter as well.
Medical segment&#39;s revenues grew 4% year over year in the last reported quarter, driven by growth in at-Home Solutions and GMPD. The segment&#39;s profit was $20 million in the fiscal third quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives, which are likely to have boosted the medical segment&#39;s results in the fiscal fourth quarter as well.
In March 2024, Cardinal Health completed the acquisition of Specialty Networks, which is likely to expand the company&#39;s offerings with physicians in the areas of urology, GI, and rheumatology. Specialty Networks is providing a proven platform in PPS analytics that the company is likely to further invest in fiscal 2025 and look to extend to other therapeutic areas such as oncology.
Per the third-quarter earnings call, CAH&#39;s integration of Specialty Networks is underway, and the reaction from the providers the company serves has been extremely encouraging. The platform&#39;s insight generation capabilities for clinicians are robust, which is likely to accelerate CAH&#39;s upstream data and research opportunities with biopharma manufacturers. The company is expected to provide further updates in this regard in the to-be-reported quarter.
The company announced its new distribution center being built in South Carolina, which, per management, features the fastest order fulfillment system per square foot in the market. The center is scheduled to open by early next fiscal year. New distribution centers are likely to aid the company&#39;s supply chain, thus improving revenues. Cardinal Health is likely to provide further updates in this regard in the to-be-reported quarter.
<h3>What the Zacks Model Unveils</h3>
Our proven model does not conclusively predict an earnings beat for Cardinal Health this time around. The combination of a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP:&nbsp;Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.17%.
Zacks Rank:&nbsp;Cardinal Health currently carries a Zacks Rank #3.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price and EPS Surprise</h3>
<img alt="Cardinal Health, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1723470107.png" style="height:263px; width:544px" title="" />
Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote
</div>
<h3>Stocks to Consider</h3>
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Phibro Animal Health&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present.
The stock has risen 59.5% year to date. PAHC&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 2.30%.
Owens &amp; Minor&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>) has an Earnings ESP of +1.54% and a Zacks Rank of 2 at present.
The stock has lost 14.6% year to date. OMI&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 11.99%.
ResMed&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) has an Earnings ESP of +2.85% and a Zacks Rank of 3 at present.
The stock has risen 16% year to date. RMD&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.81%.
<a href="https://www.zacks.com/stock/news/2320761/what-s-in-store-for-cardinal-health-cah-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2320761">To read this article on Zacks.com click here.</a>

Health Care

General

What's in Store for Cardinal Health in Q4 Earnings?

Cencora (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>) is scheduled to release third-quarter fiscal 2024 results on Jul 31, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 4.11%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%.
<h3>Q3 Estimates</h3>
The Zacks Consensus Estimate for revenues is pegged at $73.58 billion, indicating an improvement of 9.9% from the top line reported in the prior-year quarter. The consensus mark for earnings is pinned at $3.18 per share, implying growth of 8.9% from the year-ago quarter&#39;s recorded number.
<h3>Factors to Note</h3>
Sustained strong growth in specialty product sales, coupled with broad-based solid performance and utilization trends across the portfolio in the U.S. Healthcare Solutions segment, might have favored COR&#39;s fiscal third-quarter performance. High demand for the recently-approved GLP-1 drugs for diabetes and/or weight loss is likely to have boosted growth. Moreover, the new distribution center in California should have continued to support its scale of supply.
The commercial COVID-19 treatments recorded lower sales in the past two quarters. This trend is likely to have continued in the soon-to-be-reported quarter. The company raised its fiscal 2024 revenue growth guidance for the U.S. Healthcare Solutions segment from 7-10% to 11-13%. This may be reflected in the fiscal third-quarter results as well. Our model expects revenues for this segment to be $66.13 billion.
Operating income at the aforementioned segment is anticipated to grow 10-12% in fiscal 2024. This is likely to be reflected in the fiscal third-quarter results. Our model predicts the segment&#39;s adjusted operating income to be $665.9 million.
Apart from this, the International Healthcare Solutions segment is expected to have exhibited solid performance on the back of increased sales in its European distribution and Canadian businesses. Moreover, the addition of products with the PharmaLex acquisition last year is likely to have generated additional revenues.
Per fiscal 2024, revenues and operating income at the International Healthcare Solutions segment are estimated to grow 4-7% and 5-8%, respectively. This is likely to be reflected in the upcoming quarterly results. Our model expects the segment&#39;s adjusted operating income and revenues to be $189.4 million and $7.35 billion, respectively.
Although revenues and operating income are likely to have been on the higher side, gross margin growth is anticipated to have been weak. This is due to higher volumes of low-margin GLP-1 products, coupled with lower volumes of high-margin government-owned COVID treatments.
<div class="chart_embed">
<h3>Cencora, Inc. Price and EPS Surprise</h3>
<img alt="Cencora, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/de/1722256757.png" style="height:263px; width:591px" title="" />
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
</div>
<h3>Earnings Beat Likely</h3>
Our proven model predicts an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Cencora has an Earnings ESP of +1.01%.
Zacks Rank: The company currently carries a Zacks Rank #3.
<h3>Other Stocks Worth a Look</h3>
Here are some other medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present.
The company&#39;s shares have surged 63% year to date. PAHC&#39;s earnings met estimates in the last reported quarter. Phibro Animal Health has a trailing four-quarter average negative earnings surprise of 2.30%.
IQVIA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iqv#NYSE">IQV</a>) has an Earnings ESP of +0.13% and a Zacks Rank of 2 at present.
Its shares have risen 3.6% year to date. IQV&#39;s earnings beat estimates in the last reported quarter. IQVIA has a trailing four-quarter average earnings surprise of 1.77%.
AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) has an Earnings ESP of +25.00% and a Zacks Rank of 3 at present.
The stock has risen 35.3% year to date. AXGN&#39;s earnings beat estimates in the last reported quarter. AxoGen has a trailing four-quarter average earnings surprise of 66.46%.
<a href="https://www.zacks.com/stock/news/2310970/cencora-cor-to-report-q3-earnings-is-a-beat-in-store?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2310970">To read this article on Zacks.com click here.</a>

Cencora to Report Q3 Earnings: Is a Beat in Store?

Stryker Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) is scheduled to release second-quarter 2024 results on Jul 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 6.38%.
<h3>Q2 Estimates</h3>
The Zacks Consensus Estimate for earnings is pegged at $2.79 per share, indicating an increase of 9.8% year over year.
The consensus mark for revenues is pinned at $5.41 billion, implying growth of 8.2% from the prior-year quarter&#39;s reported figure.
<h3>Factors to Note</h3>
Stryker&#39;s MedSurg and Neurotechnology segment witnessed substantial sales growth on the back of the robust performance of its subsegments in the past two quarters. Strong performances in the United States, Canada, Australia, Europe, Japan and most emerging markets also boosted revenues. This trend is likely to have continued in the second quarter.
Growth across Orthopaedics &amp; Spine&#39;s Hip, Knee, and Trauma and Extremities subsegments might have favored the segment&#39;s performance on the back of continued procedural growth, strong uptake of the Insignia Hip Stem and robust Mako sales.
Stryker is committed to the sustained expansion of Mako, reflecting robust demand for this differentiated robotic technology. This heightened demand, along with rising installations, is likely to have contributed to the Orthopaedics &amp; Spine segment&#39;s performance in the soon-to-be-reported quarter. Moreover, an improving hospital budget is likely to have kept the order book strong.
SYK witnessed a very strong momentum for its 1788 camera system since its launch in September 2023. The strong initial uptake might have continued in the soon-to-be-reported quarter, thereby driving additional revenues. Moreover, the launch of the Gamma4 Hip Fracture Nailing System in Europe and the LIFEPAK 35 monitor/defibrillator in the United States is likely to have brought in additional revenues during the second quarter.
The Zacks Consensus Estimate for the MedSurg and Neurotechnology, and the Orthopaedics &amp; Spine segments&#39; sales is pegged at $3.12 billion and $2.29 billion, respectively. U.S. and international sales are estimated to be $3.98 billion and $1.39 billion, respectively.
The company&#39;s prospects in 2024 seem promising on the back of ongoing procedural recovery, a strong order book for capital equipment and an improvement in price, along with a strong pipeline of innovation. However, the ongoing pressure in China due to volume-based procurement policy is likely to have partially offset international growth.
Stryker is working toward alleviating the ongoing inflationary pressure. It continued to recognize improved pricing and reduced cost pressure in the past couple of quarters. This is likely to have benefited gross margin during the second quarter.
The company is also looking to expand its presence in the market through acquisitions. In June, it signed a deal to acquire Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. SYK may provide its integration synergies for SERF SAS on its second-quarter earnings call.
<div class="chart_embed">
<h3>Stryker Corporation Price and EPS Surprise</h3>
<img alt="Stryker Corporation Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/a6/1722256548.png" style="height:263px; width:601px" title="" />
Stryker Corporation price-eps-surprise | Stryker Corporation Quote
</div>
<h3>What the Zacks Model Unveils</h3>
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is 0.00% for SYK.
Zacks Rank: The company carries a Zacks Rank #3 at present.
<h3>Stocks Worth a Look</h3>
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present.
The company&#39;s shares have surged 63% year to date. PAHC&#39;s earnings met estimates in the last reported quarter. Phibro Animal Health has a trailing four-quarter average negative earnings surprise of 2.30%.
IQVIA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iqv#NYSE">IQV</a>) has an Earnings ESP of +0.13% and a Zacks Rank of 2 at present.
Its shares have risen 3.6% year to date. IQV&#39;s earnings beat estimates in the last reported quarter. IQVIA has a trailing four-quarter average earnings surprise of 1.77%.
AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) has an Earnings ESP of +25.00% and a Zacks Rank of 3 at present.
The stock has risen 35.3% year to date. AXGN&#39;s earnings beat estimates in the last reported quarter. AxoGen has a trailing four-quarter average earnings surprise of 66.46%.
<a href="https://www.zacks.com/stock/news/2310969/stryker-syk-to-report-q2-earnings-what-s-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2310969">To read this article on Zacks.com click here.</a>

Biotech

Stryker to Report Q2 Earnings: What's in the Cards?

Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company&#39;s changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Phibro basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Phibro imply an improvement in the company&#39;s underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Earnings Estimate Revisions for Phibro
For the fiscal year ending June 2024, this maker of animal health products and nutritional supplements is expected to earn $1.13 per share, which is a change of -6.6% from the year-ago reported number.
Analysts have been steadily raising their estimates for Phibro. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.9%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of Phibro to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2291028/phibro-pahc-upgraded-to-strong-buy-what-does-it-mean-for-the-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2291028">To read this article on Zacks.com click here.</a>

Upgrades

Phibro Upgraded to Strong Buy: What Does It Mean for the Stock?

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $10 to $13.

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $13

Phibro Animal Health Affirms FY24 Adj. EPS $1.04-$1.16 Vs $1.10 Est.; Revenue $980M-$1.020B Vs $999.037M

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $263.200 million which beat the analyst consensus estimate of $254.825 million by 3.29 percent. This is a 7.12 percent increase over sales of $245.700 million the same period last year.

Phibro Animal Health Q3 2024 Adj EPS $0.31 Beats $0.29 Estimate, Sales $263.200M Beat $254.825M Estimate

Shares of Clever Leaves Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLVR#NASDAQ">CLVR</a>) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations.
Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Deciphera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.</li>
<li>Collective Audience, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAUD#NASDAQ">CAUD</a>) gained 50.4% to $0.6002 after the company announced a strategic partnership with Insticator.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares gained 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.</li>
<li>Koninklijke Philips N.V.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares climbed 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) gained 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 25% to $3.9414 after the company announced the California Air Resources Board has approved the 2024 Mullen THREE for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) climbed 25% to $1.7990.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) rose 23.9% to $6.06 after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer&#8217;s Disease.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 23.8% to $2.25. HWH International recently announced that it entered into a joint venture to build its travel business in Asia.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) jumped 22% to $0.2948.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 20.7% to $7.53.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 19% to $1.0250.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) rose 17.8% to $0.7403.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) gained 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.</li>
<li>Heartland Financial USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NASDAQ">HTLF</a>) gained 17.2% to $41.86 after UMB Financial announced it will acquire the company.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) rose 14.6% to $50.08.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) climbed 14.3% to $4.4350. Shares of lithium stocks traded higher, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) gained 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.</li>
<li>Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) rose 11.2% to $4.9182 on FDA clearance of its IND application for PM359.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 10.5% to $185.94 on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) rose 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.</li>
<li>Fulton Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) jumped 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.</li>
<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) gained 8.2% to $1.3850.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Annovis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NASDAQ">ANVS</a>) dipped 57% to $7.72 after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer&#8217;s. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) fell 48.8% to $8.25 after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) shares declined 30.3% to $1.6101 after dipping around 78% on Friday.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 21.8% to $4.8440 after the company announced the exercise of warrants for $4.4 million in gross proceeds.</li>
<li>China Jo-Jo Drugstores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJJD#NASDAQ">CJJD</a>) dipped 21% to $2.29 after the company announced a $1.53 million registered direct offering.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) fell 19.5% to $0.56 after the company said the unaudited financial statements for the quarterly periods ended March 31, 2023, June 30, 2023 and Sept 30, 2023 should no longer be relied on.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) fell 19% to $0.1399. iSun, last week, announced rescission of reverse stock split.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares fell 18.8% to $4.10 after tumbling 70% on Friday.</li>
<li>Top KingWin Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCJH#NASDAQ">TCJH</a>) fell 18% to $0.7301.</li>
<li>STRATA Skin Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) dipped 17.3% to $0.43. The company announced a 1-for-10 reverse stock split.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) fell 16.5% to $6.68.</li>
<li>Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) declined 15.6% to $1.1492.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) fell 15.3% to $7.00.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) shares fell 13.5% to $1.41 after jumping 34% on Friday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 10.4% to $3.0550. Wedbush analyst Alicia Reese reiterated AMC with a Neutral and maintained a $4 price target.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined 10.1% to $1.3493 after declining over 5% on Friday.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) fell 9.9% to $7.09 following first-quarter results.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) dipped 9.7% to $9.90 after the company reported worse-than-expected first-quarter financial results and signed a definitive merger with Territorial Bancorp.</li>
<li>Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares declined 9.3% to $21.55 after the company missed first-quarter EPS and sales estimates.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) fell 9.1% to $16.16 after the company disclosed it estimates it could have to pay up to €1.3 billion related to its Postbank litigation.</li>
<li>Altimmune, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell 9.4% to $6.58 after Guggenheim downgraded the stock from Buy to Neutral.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) fell 8.6% to $17.68.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) declined 8% to $2.7050.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 7.5% to $14.31.</li>
<li>Civeo Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) fell 7% to $23.25.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38491128/nxp-semiconductors-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-ear">NXP Semiconductors Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Intraday Update

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CGEM

CJJD

CLVR

CSSE

CVEO

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PRME

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Deciphera Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 51.46% to $0.24. The market value of their outstanding shares is at $11.9 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 32.17% to $0.05. The market value of their outstanding shares is at $6.5 million. </li>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock moved upwards by 28.02% to $26.98. The company's market cap stands at $24.4 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) shares rose 26.94% to $16.16. The market value of their outstanding shares is at $654.5 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares rose 25.36% to $47.5. The company's market cap stands at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) stock declined by 57.7% to $7.62 during Monday's regular session. The company's market cap stands at $83.9 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares decreased by 49.07% to $8.2. The market value of their outstanding shares is at $8.7 million. </li>
<li>SELLAS Life Sciences Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) shares fell 16.44% to $1.22. The company's market cap stands at $68.6 million. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) stock fell 15.69% to $0.43. The company's market cap stands at $15.2 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares declined by 15.41% to $0.59. The market value of their outstanding shares is at $5.2 million. </li>
<li>Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) stock decreased by 13.15% to $3.54. The market value of their outstanding shares is at $318.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQST

CLDI

SINT

12 Health Care Stocks Moving In Monday's Intraday Session

WIIM

Phibro Animal Health shares are trading higher after the company announced it will acquire Zoetis' medicated feed additive product portfolio.

Phibro Animal declares $0.12 dividend

Phibro Animal Non-GAAP EPS of $0.41 beats by $0.08, revenue of $273.2M beats by $12.71M

Phibro Animal Health Corporation 2024 Q4 - Results - Earnings Call Presentation

Phibro Animal Health Corporation (PAHC) Q4 2024 Earnings Call Transcript

In a report released today, Balaji Prasad from Barclays assigned a Sell rating to Phibro Animal Health (PAHC – Research Report), with a price targe...

Phibro Animal Health (PAHC) Receives a Sell from Barclays

The pet care industry is expected to witness immense growth owing to a surge in pet adoptions, veterinary innovations, and rising disposable income. Thus, one could scoop up shares of fundamentally solid pet-care stocks with tail-wagging potential, like Zoetis (ZTS), Chewy (CHWY), and PetIQ (PETQ). Read more… The pet care industry is witnessing remarkable growth driven by a surge in global pet adoptions and significant advancements in veterinary care. Concurrently, the increased investment by pet owners in care and accessories is expected to bolster strong growth prospects for the sector.
Given this backdrop, investors could consider loading up on shares of fundamentally sound pet care stocks Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>), and  PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>) that seem well positioned to capitalize on the industry tailwinds.
In recent times, pet adoption has increased drastically, and the trend continues. A substantial number of American households own a pet, with dogs being the most popular. <a href="https://www.forbes.com/advisor/pet-insurance/pet-adoption-statistics/">Pet ownership</a> is increasing particularly amongst young generations, with millennials having the highest share of pet owners at 33%.
Advancements in technology are also transforming veterinary medicine, leading to improved diagnostic capabilities, innovative treatment options, and enhanced medical devices. Innovations like telemedicine, digital imaging, minimally invasive surgeries, and advanced laboratory diagnostics have significantly upgraded the quality of animal care and broadened the scope of veterinary services.
According to a Grand View Research study, the U.S. veterinary medicine market is expected to grow at <a href="https://www.grandviewresearch.com/industry-analysis/us-veterinary-medicine-market-report">a CAGR of 6.8%</a> from 2024 to 2030. This growth is projected to push the market to a substantial $21.80 billion, reflecting the increasing demand for advanced veterinary care.
Moreover, an increase in disposable income has further fueled higher pet ownership rates, prompting greater investment in pet care products like accessories, health items, and fashion. According to the Bureau of Economic Analysis data, disposable personal income <a href="https://www.bea.gov/news/2024/personal-income-and-outlays-july-2024">rose by $54.8 billion</a> or 0.3% in July 2024.
Looking forward, as per a report by Mordor Intelligence, the pet care market is expected to reach $24.59 billion by 2029, expanding at a <a href="https://www.mordorintelligence.com/industry-reports/pet-care-market">CAGR of 4.2%</a>.
Given these positive trends, let's discuss the fundamentals of three pet-care stocks, starting with #3.
Stock #3: Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>)
ZTS develops, manufactures, and commercializes medicines, vaccines, and diagnostic products and services for animal health. It operates in eight core species and seven major product categories, with products sold in 45 countries and over 100 countries. The company operates through two segments: United States and International.
On April 28, ZTS <a href="https://investor.zoetis.com/news/news-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx">announced its definitive agreement</a> with Phibro Animal Health Corporation (<a href="https://stocknews.com/stock/PAHC/">PAHC</a>), a global leader in animal health and nutrition. As part of this deal, PAHC will acquire ZTS' medicated feed additive (MFA) product portfolio, select water-soluble products, and related assets for around $350 million.
The transaction would allow ZTS to streamline its focus on core areas while unlocking capital for strategic growth opportunities.
For the fiscal 2024 second quarter that ended on June 30, 2024, ZTS' revenue increased 8.3% year-over-year to $2.36 billion. Its non-GAAP gross profit grew 7.4% from the year-ago value to $1.69 million.
In addition, non-GAAP net income attributable to ZTS came in at $711 million or $1.56 per share, indicating a year-over-year growth of 9% and 10.6%, respectively.
Analysts expect ZTS' revenue for the fiscal third quarter (ending September 2024) to increase 6.4% year-over-year to $2.29 billion. Meanwhile, its EPS for the same quarter is expected to grow 7.7% from the prior year's period to $1.46. Furthermore, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of ZTS have surged 3.7% in the past month and 9% in the past three months to close the last trading session at $187.33.
ZTS' bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ZTS has a B grade for Quality and Stability. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, the stock is ranked #39 out of 158 stocks.
<a href="https://stocknews.com/stock/ZTS/">Click here</a> to access additional ZTS ratings for Sentiment, Momentum, Growth, and Value.
Stock #2: Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>)
CHWY operates as a pure-play e-commerce business. It offers pet food, treats, supplies, and medications, along with other pet health products. The company also provides pet services for dogs, cats, fish, birds, small pets, horses, and reptiles. These are available through its retail websites and mobile applications.
For the fiscal 2024 second quarter ended on July 28, 2024, CHWY's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.6% year-over-year to $2.86 billion. Its gross profit rose 7% from the year-ago value to $843.84 million. Additionally, the company's adjusted EBITDA of $144.84 million indicates an increase of 64.3% from the prior year's quarter.
Furthermore, the company's adjusted net income and adjusted EPS came in at $104.79 million and $0.24, up 62.3% and 60% from the previous year's period, respectively.
For the fiscal 2025 third quarter ending October 2024, CHWY's revenue and EPS are expected to increase 4.2% and 49.9% year-over-year to $2.85 billion and $0.22, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters, which is impressive.
Shares of CHWY have gained 22.1% over the past three months and 53.3% over the past six months to close the trading session at $27.15.
CHWY's sound fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CHWY has an A grade for Growth and a B grade for Quality and Sentiment.
Within the A-rated <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry, CHWY is ranked #15 among the 52 stocks.
In addition to the POWR Ratings we've stated above, we also have CHWY's ratings for Stability, Value, and Momentum. Get all CHWY ratings <a href="https://stocknews.com/stock/CHWY/">here</a>.
Stock #1: PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>)
PETQ is a pet medication and wellness company that offers veterinary products and services. The company's Products segment distributes value-branded and third-party products for dogs and cats. Meanwhile, the Services segment offers diagnostic tests, vaccinations, and specialty medications.
On August 7, PETQ <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-enters-definitive-agreement-be-acquired-bansk-group">announced its acquisition</a> by Bansk Group, a consumer-focused private investment firm. Bansk will acquire all outstanding shares of PETQ's common stock at $31.00 per share, valuing the transaction at approximately $1.5 billion.
Cord Christensen, Founder, Chairman, and CEO of PETQ, stated that the Board considers this transaction a positive outcome for both the company and its stockholders.
On March 14, PETQ announced the <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-celebrates-expansion-mintiesr-dental-treats-brand">launch of its new product</a>, Minties&#xAE; dental treats, designed for tiny/small, medium, and large-sized dogs, as well as cats. By continuously innovating and introducing new products to the pet-care market, the company is positioned to increase its popularity and expand its customer base.
PETQ's total net sales increased 4.6% year-over-year to $328.94 million for the fiscal 2024 second quarter, which ended on July 30. Its gross profit rose 19.5% from the year-ago value to $88.28 million.
Moreover, the company's operating income came in at $25.58 million, increasing 36.7% from the prior year's quarter. Plus, its adjusted EBITDA was reported to be $39.04 million, indicating an increase of 18.8% year-over-year.
In addition, the company's adjusted net income came in at $24.42 million or $0.70 per share, up 82.2% and 52.2% from the prior year's quarter, respectively.
The consensus revenue and EPS estimates of $1.16 billion and $1.56 for the fiscal year ending December 2024 exhibit a year-over-year rise of 4.9% and 25.6%, respectively. Moreover, the company has topped the consensus EPS estimates in all the four trailing quarters.
Shares of PETQ have gained 47.8% over the past three months and 81.8% over the past six months to close the trading session at $30.52.
PETQ's solid fundamentals are echoed in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PETQ has an A grade for Growth and a B for Value. It is ranked #19 out of 62 stocks in the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry.
Beyond what is stated above, we've also rated PETQ for Sentiment, Stability, Momentum, and Quality. Get all PETQ ratings <a href="https://stocknews.com/stock/PETQ/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
ZTS shares were unchanged in premarket trading Thursday. Year-to-date, ZTS has declined -4.37%, versus a 16.65% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/zts-chwy-petq-pahc-3-pet-care-stocks-with-tail-wagging-potential/>3 Pet Care Stocks With Tail-Wagging Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pet Care Stocks With Tail-Wagging Potential

In a report released today, Balaji Prasad from Barclays maintained a Sell rating on Phibro Animal Health (PAHC – Research Report), with a price tar...

Barclays Remains a Sell on Phibro Animal Health (PAHC)

Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health (PAHC – Research Report) yesterday and set a pri...

Bank of America Securities Sticks to Its Sell Rating for Phibro Animal Health (PAHC)

An update from Phibro Animal Health ( ($PAHC) ) is now available. Phibro Animal Health Corporation has acquired Zoetis Inc.'s medicated feed additi...

Phibro Animal Health Expands Portfolio with Zoetis Acquisition

CHWY

PETQ

Press Releases

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation to Participate in Stifel Dental and Animal Health (Jaws & Paws) Conference

Phibro Animal Health Corporation Releases Third Annual ESG Report: Connections that Advance Animal Health, Nutrition and Sustainability

Phibro Animal Health Corporation Declares Quarterly Dividend

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2024 Results

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

Comments

Phibro Animal Health

Phibro Animal Health (PAHC) Opzioni

Phibro Animal Health (NASDAQ:PAHC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO